BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. MATERIALS AND METHODS: Patient databases at four cancer institutions were queried. The Fisher exact test was performed to test the association of clinical and molecular markers. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and compared by the log-rank test. Twelve- and 24-month PFS rates were compared by the Z test. RESULTS: A total of 60 patients with CRC with MMR-D/microsatellite instability-high who previously received ICIs were identified. Patients with liver metastasis had a lower overall response rate as compared with other sites of metastasis (36.4% vs. 68.7%; p = .081). Patients with MLH1/PMS2 loss had worse 1-year and 2-year PFS rates compared with patients with MSH2/MSH6 loss (84.2% vs. 57.8% and 78.2% vs. 54.2%, respectively; p < .001). There were improved 1-year and 2-year PFS rates in patients with wild-type BRAF when compared with patients with BRAF V600E mutation (73.3% vs. 40%, and 73.3% vs. 26.7%; respectively; p < .001). Patients aged >65 had significantly worse PFS rates as compared with patients aged ≤65 (p < .001). CONCLUSION: BRAF V600E mutation, MLH1 and/or PMS2 loss, as well as age >65 years and liver metastasis, may be predictive of duration of ICI response in patients with MMR-D CRC. Larger cohorts are needed to confirm our findings. IMPLICATIONS FOR PRACTICE: The results of this study reveal clinically important biomarkers that potentially predict immune checkpoint inhibitor response in patients with mismatch repair-deficient colorectal cancer.
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. MATERIALS AND METHODS: Patient databases at four cancer institutions were queried. The Fisher exact test was performed to test the association of clinical and molecular markers. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and compared by the log-rank test. Twelve- and 24-month PFS rates were compared by the Z test. RESULTS: A total of 60 patients with CRC with MMR-D/microsatellite instability-high who previously received ICIs were identified. Patients with liver metastasis had a lower overall response rate as compared with other sites of metastasis (36.4% vs. 68.7%; p = .081). Patients with MLH1/PMS2 loss had worse 1-year and 2-year PFS rates compared with patients with MSH2/MSH6 loss (84.2% vs. 57.8% and 78.2% vs. 54.2%, respectively; p < .001). There were improved 1-year and 2-year PFS rates in patients with wild-type BRAF when compared with patients with BRAF V600E mutation (73.3% vs. 40%, and 73.3% vs. 26.7%; respectively; p < .001). Patients aged >65 had significantly worse PFS rates as compared with patients aged ≤65 (p < .001). CONCLUSION: BRAF V600E mutation, MLH1 and/or PMS2 loss, as well as age >65 years and liver metastasis, may be predictive of duration of ICI response in patients with MMR-D CRC. Larger cohorts are needed to confirm our findings. IMPLICATIONS FOR PRACTICE: The results of this study reveal clinically important biomarkers that potentially predict immune checkpoint inhibitor response in patients with mismatch repair-deficient colorectal cancer.
Authors: Christoph Engel; Aysel Ahadova; Toni T Seppälä; Stefan Aretz; Marloes Bigirwamungu-Bargeman; Hendrik Bläker; Karolin Bucksch; Reinhard Büttner; Wouter T de Vos Tot Nederveen Cappel; Volker Endris; Elke Holinski-Feder; Stefanie Holzapfel; Robert Hüneburg; Maarten A J M Jacobs; Jan J Koornstra; Alexandra M Langers; Anna Lepistö; Monika Morak; Gabriela Möslein; Päivi Peltomäki; Kirsi Pylvänäinen; Nils Rahner; Laura Renkonen-Sinisalo; Karsten Schulmann; Verena Steinke-Lange; Albrecht Stenzinger; Christian P Strassburg; Paul C van de Meeberg; Mariette van Kouwen; Monique van Leerdam; Deepak B Vangala; Juda Vecht; Marie-Louise Verhulst; Magnus von Knebel Doeberitz; Jürgen Weitz; Silke Zachariae; Markus Loeffler; Jukka-Pekka Mecklin; Matthias Kloor; Hans F Vasen Journal: Gastroenterology Date: 2020-01-08 Impact factor: 22.682
Authors: Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott Journal: Hered Cancer Clin Pract Date: 2010-05-21 Impact factor: 2.857
Authors: Dennis J Ahnen; Sally W Wade; Whitney F Jones; Randa Sifri; Jose Mendoza Silveiras; Jasmine Greenamyer; Stephanie Guiffre; Jennifer Axilbund; Andrew Spiegel; Y Nancy You Journal: Mayo Clin Proc Date: 2014-01-04 Impact factor: 7.616
Authors: James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer Journal: Clin Cancer Res Date: 2011-12-12 Impact factor: 12.531
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: R Parsons; G M Li; M J Longley; W H Fang; N Papadopoulos; J Jen; A de la Chapelle; K W Kinzler; B Vogelstein; P Modrich Journal: Cell Date: 1993-12-17 Impact factor: 41.582
Authors: Paul C Tumeh; Matthew D Hellmann; Omid Hamid; Katy K Tsai; Kimberly L Loo; Matthew A Gubens; Michael Rosenblum; Christina L Harview; Janis M Taube; Nathan Handley; Neharika Khurana; Adi Nosrati; Matthew F Krummel; Andrew Tucker; Eduardo V Sosa; Phillip J Sanchez; Nooriel Banayan; Juan C Osorio; Dan L Nguyen-Kim; Jeremy Chang; I Peter Shintaku; Peter D Boasberg; Emma J Taylor; Pamela N Munster; Alain P Algazi; Bartosz Chmielowski; Reinhard Dummer; Tristan R Grogan; David Elashoff; Jimmy Hwang; Simone M Goldinger; Edward B Garon; Robert H Pierce; Adil Daud Journal: Cancer Immunol Res Date: 2017-04-14 Impact factor: 12.020
Authors: Elaine Tan; Junmin Whiting; Hao Xie; Iman Imanirad; Estrella Carballido; Seth Felder; Jessica Frakes; Quanxing Mo; Christine Walko; Jennifer B Permuth; Katelyn Sommerer; Richard Kim; Daniel A Anaya; Jason B Fleming; Ibrahim Halil Sahin Journal: Oncologist Date: 2022-03-11